Corvus Pharmaceuticals, Inc.
CRVS
$6.94
-$0.32-4.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.39M | 2.47M | 2.13M | 2.03M | 1.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.26M | 9.92M | 8.11M | 7.26M | 5.94M |
| Operating Income | -10.26M | -9.92M | -8.11M | -7.26M | -5.94M |
| Income Before Tax | -8.00M | 15.19M | -12.11M | -40.22M | -4.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.00M | 15.19M | -12.11M | -40.22M | -4.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.00M | 15.19M | -12.11M | -40.22M | -4.26M |
| EBIT | -10.26M | -9.92M | -8.11M | -7.26M | -5.94M |
| EBITDA | -10.23M | -9.90M | -8.09M | -7.23M | -5.91M |
| EPS Basic | -0.10 | 0.21 | -0.18 | -0.60 | -0.07 |
| Normalized Basic EPS | -0.06 | 0.13 | -0.11 | -0.38 | -0.04 |
| EPS Diluted | -0.10 | -0.13 | -0.18 | -0.60 | -0.07 |
| Normalized Diluted EPS | -0.06 | 0.13 | -0.11 | -0.38 | -0.04 |
| Average Basic Shares Outstanding | 77.77M | 72.13M | 68.35M | 66.70M | 59.71M |
| Average Diluted Shares Outstanding | 77.77M | 75.15M | 68.35M | 66.70M | 59.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |